Layer, Chiang, et al. Genome Biology
Tacere Takes Back Asian Rights to HCV Program as It Waits on Pfizer
Although Pfizer's license to the HCV program in markets outside of Asia remains in effect, major restructuring at the big pharma has raised questions about the future of the arrangement.
New to GenomeWeb? Register here quickly.